Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

83.44 -2.55 (-2.96%)
Streaming Delayed Price Updated: 12:29 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
94 95 Next >
AI Unleashes a New Era: Biopharma’s Accelerated Revolution and the Rise of TechBio
The biopharmaceutical industry is undergoing an immediate and profound transformation, as Artificial Intelligence (AI) rapidly compresses timelines, drastically reduces costs, and significantly... 
Via TokenRing AI
Topics Animal Testing Artificial Intelligence Economy
Amgen Solidifies Biotech Dividend Prowess with $2.38 Q4 2025 Payout
Thousand Oaks, CA – October 31, 2025 – Amgen (NASDAQ: AMGN), a leading biotechnology giant, has declared a quarterly dividend of $2.38 per share for the fourth quarter of 2025. This significant... 
Via MarketMinute
Topics Intellectual Property
AI Revolutionizes Pharma: Smarter Excipients for Safer, More Potent Drugs
San Francisco, CA – October 31, 2025 – Artificial intelligence (AI) is ushering in a transformative era for the pharmaceutical industry, particularly in the often-overlooked yet critical domain of... 
Via TokenRing AI
Topics Artificial Intelligence Supply Chain
AI: The Pharmaceutical Sector’s New Catalyst for a Healthier Future
The pharmaceutical industry is in the midst of a profound and rapid transformation, driven by the pervasive integration of Artificial Intelligence (AI). What was once a futuristic concept is, by late... 
Via TokenRing AI
Topics Animal Testing Artificial Intelligence Economy
Merck Q3 2025 Earnings Call Transcript
Merck Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain
As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the GLP-1 gold rush. 
Via Benzinga
Topics ETFs
Earnings Scheduled For October 30, 2025
 
Via Benzinga
Merck & Co Unusual Options Activity
 
Via Benzinga
Meta Tumbles 10%, Google Marks Historic Rally: What's Moving Markets Thursday?
Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the mega-caps and the lingering impact of hawkish remarks from Fed Chair Jerome... 
Via Benzinga
Topics Economy
Merck Ready For Larger Than $15 Billion Deals, Raises Annual Profit Outlook
Merck shares dipped after strong earnings and higher profit guidance, as the company narrowed its 2025 sales forecast amid mixed product performance. 
Via Benzinga
Merck’s (NYSE:MRK) Q3 Sales Top Estimates
Global pharmaceutical company Merck (NYSE:MRK) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 3.7% year on year to $17.28 billion. The company expects the full year’s revenue to be... 
Via StockStory
Merck & Co. Inc. (NYSE:MRK) Q3 2025 Earnings Beat Expectations Despite Stock Decline
Merck Q3 2025 earnings beat estimates with strong sales and EPS growth, driven by KEYTRUDA and WINREVAIR, yet shares fell on guidance. 
Via Chartmill
Topics Earnings
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
 
Via Benzinga
Dow Jones Stock Merck Tops Expectations, But Gardasil Challenges Remain
The company sells a notable vaccine to prevent human papillomavirus. But sales are struggling. 
Via Investor's Business Daily
Topics Earnings Stocks
Merck (MRK) Reports Earnings Tomorrow: What To Expect
Global pharmaceutical company Merck (NYSE:MRK) will be reporting earnings this Thursday morning. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
Looking At Merck & Co's Recent Unusual Options Activity
 
Via Benzinga
Merck's New Cancer Therapy Combo Shows Significant Edge Over Rivals In Renal Cancer
Merck and Eisai report Phase 3 results showing Welireg plus Lenvima significantly improved progression-free survival in advanced kidney cancer. 
Via Benzinga
Healthcare Sector Navigates Volatile Waters as S&P 500 Closes: A Deep Dive into Key Market Drivers
As the closing bell rings on October 27, 2025, the S&P 500 Healthcare sector stands at a critical juncture, exhibiting the nuanced volatility that defines this essential yet complex segment of the... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
3 Dividend-Paying Drug Stocks to Buy at a Discount
Some of the largest drugmakers in the world are trading at attractive valuations. Are they worth buying? 
Via The Motley Fool
Topics Intellectual Property
How Is The Market Feeling About Merck & Co Inc?
 
Via Benzinga
3 Healthcare Stocks to Buy Hand Over Fist in October
One growth stock, one high-yield stock, and one Dividend King -- you should find something you like here as October draws to a close. 
Via The Motley Fool
Topics Intellectual Property
3 Healthcare Stocks That Are Screaming Deals Right Now
These bargains could prove good for your financial health. 
Via The Motley Fool
Topics Intellectual Property
Flash PMI: The Early Warning System Guiding the Federal Reserve's Hand
Flash Purchasing Managers' Index (PMI) data, a critical economic bellwether, continues to command significant attention from financial markets and policymakers alike. Released typically a week or two... 
Via MarketMinute
Topics Bonds Economy Supply Chain
ONEOK’s 6% Dividend Draws Smart Money Despite a Nearly 30% Drop
ONEOK’s 6% Dividend Draws Smart Money Despite a Nearly 30% Drop 
Via The Motley Fool
Topics Energy Regulatory Compliance
Why Some Investors Are Taking Profits on JPMorgan After Its Big Rally
Why Some Investors Are Taking Profits on JPMorgan After Its Big Rally 
Via The Motley Fool
AI Revolutionizes Drug Discovery and Personalized Medicine: A New Era of Healthcare
The pharmaceutical and biotechnology industries are undergoing a profound transformation, driven by an urgent need for more efficient drug discovery and development processes and the paradigm shift... 
Via TokenRing AI
Topics Animal Testing Artificial Intelligence
What's Going On With Summit Therapeutics Stock On Monday?
Summit Therapeutics shares Phase 3 data showing ivonescimab cut cancer progression risk by 40% and plans BLA submission in late 2025. 
Via Benzinga
2 Beaten-Down Stocks to Buy and Hold for the Next Decade
That's plenty of time for these drugmakers to move past their challenges. 
Via The Motley Fool
Market Minute: Dow Soars, Apple Hits Record High as 20-Day Government Shutdown Fuels Gold Rally
The U.S. financial markets opened the week with a robust performance on October 20, 2025, as the Dow Jones Industrial Average (DJIA) extended its gains, and tech giant Apple Inc. (NASDAQ: AAPL) reached... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
Biotech Boom: Strategic Realignments and AI Integration Fuel Investor Focus, Signaling Broader Market Shifts
The biotechnology sector is currently experiencing a significant surge in investor attention, characterized by a blend of cautious optimism and strategic focus. As of October 2025, this heightened... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
< Previous 1 2 3 4 5 6 7 8 9
...
94 95 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.